// App-Quantinova.ai

TCT-111 : Efficacy and safety of glycoprotein IIb/IIIa inhibitors on top of a potent P2Y12 inhibitor in STEMI: A pre-specified sub-analysis of the ATLANTIC trial

Researchers

Presenter

  • Anne Tavenier

Principal Investigators

  • Rik Hermanides

  • Enrico Fabris

  • JOHANNE SILVAIN

  • Jens Lassen

  • Leonardo Bolognese

  • Warren Cantor

  • Kurt Huber

  • Bela Merkely

  • Uwe Zeymer

  • Christian Hamm

  • Gilles Montalescot

  • Arnoud van 't Hof

Medical Centers

  • Ospedale San donato Arezzo, Italy, Florence, Arezzo, Italy

  • Maastricht University Medical Center, Maastricht, Netherlands

  • Isala Klinieken Zwolle, Zwolle, Netherlands

  • Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France

  • The Heart Centre, Rigshospitalet, Copenhagen, Denmark

  • Herzzentrum Ludwigshafen, Ludwigshafen, Germany

  • Isala, Zwolle, Netherlands

  • Wilheminen Hospital, Vienna, Austria

  • Cardiovascular Department, University of Trieste, Trieste, Trieste, Italy

  • Kerckhoff Clinic, Bad Nauheim, Germany

  • ACTION group - Hopital Pitie-Salpetriere, Paris, France

  • Southlake Regional Health Center, Newmarket, Ontario, Canada

  • Semmelweis University Heart and Vascular Center, Budapest, Hungary

Locations

  • Italy

  • Germany

  • France

  • Netherlands

  • Austria

  • Hungary

  • Denmark

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Myocardial infarction

  • Venous thrombosis

Biomarkers

  • Glycosylphosphatidylinositol

Drug/Treatment

  • Clopidogrel bisulfate

  • Ticagrelor

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved